There were documented intense circumstances of peliosis hepatis, sometimes linked to liver failure and intra-abdominal hemorrhage; liver tumors, from time to time fatal; and blood lipid improvements connected to increased possibility of atherosclerosis led FDA to remove approval in June 2023. Supplemental warnings include the pitfalls associated with cholestatic hepatitis, https://superdrol56789.blogripley.com/35960331/equipoise-for-dummies